14th Milan Congress on Innovative Anticancer Therapy

Rationale

The 14th “Milan Congress on Anticancer Innovative Therapy” Conference will involve leading international experts in the field of immuno-oncology and biologic therapy of cancer to improve the potential, opportunities and challenges of the new approaches. The increasing knowledge of the molecular mechanisms responsible for neoplastic progression, the characterization of tumor microenvironment, and the immunological/angiogenetic mechanisms regulating the tumor-host interaction, allowed us to identify and apply more effective anti-cancer biogical and immunological treatments.
To date, the immuno-biotherapy is a continuously evolving treatment modality and it is currently integrated into the treatment algorythms of several different tumor types.
This conference explores topics that will appeal to clinicians, as well as, basic, translational, and clinical scientists ranging from academics to industry. As in the past, the meeting will provide a highly interactive forum in which leading experts will discuss clinical and pre-clinical data, providing the audience with a broad overview of the most recent achievements in cancer biologic and immunologic therapy, for example in the neoadjuvant setting of melanoma patients.
Finally, a wide spectrum of evolving topics in cancer research such as epigenetic drugs, CART cell-based new constructs and the application of artificial intelligence will be analyzed in view on introducing them to the clinical setting.

First Announcement

Programma

Locandina

Responsabile S.S. Immunoterapia
Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
Direttore Dipartimento di Oncoematologia
Fondazione IRCCS Istituto Nazionale Tumori and University of Milan, Milan, Italy
Responsabile S.S. Oncologia Medica Melanomi
Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy